All articles tagged with #biotech startups
NewLimit, a South San Francisco longevity biotech, secured $435 million in a Series C led by Founders Fund (with Thrive Capital, Lilly Ventures, Nat Friedman, and Daniel Gross) valuing the company at about $3.1 billion as it moves toward its first liver-focused clinical trial. Founders include Brian Armstrong, Blake Byers, and Jacob Kimmel, with prior rounds of $130 million in May 2025 and $45 million in October 2025.
The rise of radiopharmaceuticals, a new cancer treatment that targets cancer cells with radioactive isotopes, is facing a significant talent shortage. This innovative approach has attracted numerous biotech startups and substantial investments, with several companies being acquired for over $1 billion. However, the industry's growth is threatened by a lack of skilled professionals needed to develop and implement these therapies.
Biotech startups are developing weight loss medications that aim to preserve or grow muscle while reducing fat, inspired by research on mice that were genetically modified to have increased lean muscle mass. These companies hope that their drugs, combined with existing obesity treatments, will lead to healthier weight loss options.